Background/Objectives: Admission hyperglycemia is frequent in COVID-19, reflecting stress hyperglycemia, systemic inflammation, and potential viral injury to pancreatic β-cells. It may serve as an early marker of severity. We assessed whether admission hyperglycemia predicts severe disease and poor outcomes in adults without diabetes. Methods: We performed a retrospective cohort study including adults hospitalized with RT-PCR/antigen-confirmed COVID-19 between August 2020 and July 2021. Patients 80 years, with prior diabetes, or on corticosteroids were excluded. Hyperglycemia was defined as fasting glucose > 106 mg/dL and classified as mild (107–180 mg/dL), moderate (181–300 mg/dL), and severe (>300 mg/dL). Clinical, laboratory, imaging, treatment, utilization, and cost parameters were analyzed. Results: Of 1009 patients, 734 (72.7%) were hyperglycemic at admission. Compared with normoglycemic patients, hyperglycemics more often developed respiratory failure (67.7% vs. 38.2%), required CPAP (9.4% vs. 1.5%), and had severe/critical disease (46.9% vs. 25.1%), ICU transfer (6.5% vs. 1.5%), and mortality (3.8% vs. 1.1%) (all p ≤ 0.0256). They also showed lymphopenia, eosinopenia, higher inflammatory and coagulation markers, longer hospitalization (12.1 vs. 10.1 days), and increased costs (EUR 1846 vs. 1043) (all p 300 mg/dL) strongly correlated with inflammation, coagulopathy, tissue injury, and radiologic severity. Conclusions: Admission hyperglycemia is a robust, easily measurable predictor of severe COVID-19 and adverse outcomes in non-diabetic adults and is associated with greater resource utilization and higher costs. Early identification may improve risk stratification. Future prospective studies should determine whether early detection and aggressive glycemic control can modify prognosis.
Rodina et al. (Wed,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: